|
Gene: TXLNG |
Gene summary for TXLNG |
Gene summary. |
Gene information | Species | Human | Gene symbol | TXLNG | Gene ID | 55787 |
Gene name | taxilin gamma | |
Gene Alias | CXorf15 | |
Cytomap | Xp22.2 | |
Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | Q9NUQ3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55787 | TXLNG | LZE4T | Human | Esophagus | ESCC | 1.35e-13 | 2.00e-01 | 0.0811 |
55787 | TXLNG | LZE5T | Human | Esophagus | ESCC | 5.34e-06 | 1.72e-01 | 0.0514 |
55787 | TXLNG | LZE7T | Human | Esophagus | ESCC | 3.25e-03 | 1.58e-01 | 0.0667 |
55787 | TXLNG | LZE8T | Human | Esophagus | ESCC | 4.37e-11 | 1.35e-01 | 0.067 |
55787 | TXLNG | LZE24T | Human | Esophagus | ESCC | 3.51e-10 | 1.24e-02 | 0.0596 |
55787 | TXLNG | LZE6T | Human | Esophagus | ESCC | 9.80e-04 | 3.02e-01 | 0.0845 |
55787 | TXLNG | P1T-E | Human | Esophagus | ESCC | 1.38e-04 | 5.65e-02 | 0.0875 |
55787 | TXLNG | P2T-E | Human | Esophagus | ESCC | 5.88e-39 | 8.51e-01 | 0.1177 |
55787 | TXLNG | P4T-E | Human | Esophagus | ESCC | 1.55e-15 | 3.94e-01 | 0.1323 |
55787 | TXLNG | P5T-E | Human | Esophagus | ESCC | 3.34e-12 | 3.00e-01 | 0.1327 |
55787 | TXLNG | P8T-E | Human | Esophagus | ESCC | 4.95e-14 | 2.83e-01 | 0.0889 |
55787 | TXLNG | P9T-E | Human | Esophagus | ESCC | 1.52e-07 | 9.34e-02 | 0.1131 |
55787 | TXLNG | P10T-E | Human | Esophagus | ESCC | 1.39e-09 | 1.09e-01 | 0.116 |
55787 | TXLNG | P11T-E | Human | Esophagus | ESCC | 1.41e-13 | 4.18e-01 | 0.1426 |
55787 | TXLNG | P12T-E | Human | Esophagus | ESCC | 9.74e-08 | 2.13e-01 | 0.1122 |
55787 | TXLNG | P15T-E | Human | Esophagus | ESCC | 2.53e-22 | 2.77e-01 | 0.1149 |
55787 | TXLNG | P16T-E | Human | Esophagus | ESCC | 5.15e-22 | 4.76e-01 | 0.1153 |
55787 | TXLNG | P17T-E | Human | Esophagus | ESCC | 9.17e-03 | 1.45e-01 | 0.1278 |
55787 | TXLNG | P19T-E | Human | Esophagus | ESCC | 9.59e-04 | 5.40e-01 | 0.1662 |
55787 | TXLNG | P20T-E | Human | Esophagus | ESCC | 1.70e-13 | 2.27e-01 | 0.1124 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000150317 | Esophagus | ESCC | ossification | 232/8552 | 408/18723 | 3.00e-06 | 3.40e-05 | 232 |
GO:000150310 | Oral cavity | OSCC | ossification | 203/7305 | 408/18723 | 5.54e-06 | 6.19e-05 | 203 |
GO:0001503110 | Thyroid | PTC | ossification | 176/5968 | 408/18723 | 9.26e-07 | 1.40e-05 | 176 |
GO:00302785 | Thyroid | PTC | regulation of ossification | 51/5968 | 115/18723 | 3.30e-03 | 1.61e-02 | 51 |
GO:000150332 | Thyroid | ATC | ossification | 206/6293 | 408/18723 | 9.23e-13 | 3.95e-11 | 206 |
GO:003027813 | Thyroid | ATC | regulation of ossification | 60/6293 | 115/18723 | 3.01e-05 | 2.51e-04 | 60 |
GO:01101492 | Thyroid | ATC | regulation of biomineralization | 45/6293 | 99/18723 | 9.34e-03 | 3.44e-02 | 45 |
GO:00701672 | Thyroid | ATC | regulation of biomineral tissue development | 44/6293 | 97/18723 | 1.05e-02 | 3.81e-02 | 44 |
GO:0030500 | Thyroid | ATC | regulation of bone mineralization | 36/6293 | 78/18723 | 1.43e-02 | 4.92e-02 | 36 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TXLNG | SNV | Missense_Mutation | novel | c.284T>G | p.Leu95Trp | p.L95W | Q9NUQ3 | protein_coding | deleterious(0.02) | benign(0.049) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TXLNG | SNV | Missense_Mutation | novel | c.1181N>C | p.Lys394Thr | p.K394T | Q9NUQ3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TXLNG | SNV | Missense_Mutation | novel | c.1508N>A | p.Ala503Asp | p.A503D | Q9NUQ3 | protein_coding | tolerated_low_confidence(0.17) | benign(0.296) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TXLNG | SNV | Missense_Mutation | c.1297N>T | p.Arg433Trp | p.R433W | Q9NUQ3 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
TXLNG | SNV | Missense_Mutation | rs143490821 | c.344N>A | p.Arg115Gln | p.R115Q | Q9NUQ3 | protein_coding | tolerated(0.16) | benign(0.428) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
TXLNG | SNV | Missense_Mutation | novel | c.386N>T | p.Arg129Met | p.R129M | Q9NUQ3 | protein_coding | deleterious(0) | possibly_damaging(0.615) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
TXLNG | SNV | Missense_Mutation | novel | c.1139N>G | p.Gln380Arg | p.Q380R | Q9NUQ3 | protein_coding | deleterious(0) | possibly_damaging(0.574) | TCGA-AX-A3FS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TXLNG | SNV | Missense_Mutation | c.202N>T | p.Gly68Cys | p.G68C | Q9NUQ3 | protein_coding | deleterious(0) | benign(0.436) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TXLNG | SNV | Missense_Mutation | rs754224589 | c.841N>A | p.Glu281Lys | p.E281K | Q9NUQ3 | protein_coding | deleterious(0.04) | probably_damaging(0.951) | TCGA-B5-A11N-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TXLNG | SNV | Missense_Mutation | novel | c.998C>T | p.Ala333Val | p.A333V | Q9NUQ3 | protein_coding | deleterious(0.03) | benign(0.106) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |